---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-003771"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-12-03T23:59:59+00:00"
generated_at: "2026-06-28T03:49:37.022635+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chemomab CMO Aharon resigns; Weiner appointed Interim CMO

## Summary
- Dr. Arnon Aharon resigned as CMO effective Feb 1, 2022; will continue 60 days and as senior advisor.
- Dr. David M. Weiner appointed Interim CMO effective immediately, part-time, based in U.S.
- Dr. Weiner has 25+ years experience; previously CEO of Amathus Therapeutics, CMO at Lumos Pharma and aTyr Pharma.
- Resignation not due to any disagreement with company or board.
- Chemomab advancing CM-101 clinical programs in fibrotic/inflammatory diseases.

## SEC filing metadata
- accession: 0001178913-21-003771
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-12-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/0001178913-21-003771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-003771
- JSON: https://secwatch.observer/filing/0001178913-21-003771.json
- Plain text: https://secwatch.observer/filing/0001178913-21-003771.txt

## Key facts
- Executive change
  Dr. Arnon Aharon resigned as Chief Medical Officer at Chemomab Therapeutics Ltd..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On November 29, 2021, Dr. Arnon Aharon notified Chemomab Therapeutics Ltd. (the “Company”) of his resignation as its Chief Medical Officer, which will enter into effect on February 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/0001178913-21-003771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.